Cimetidine has been reported as suppressing the excess parathyroid hormone secretion and hypercalcaemia seen in hyperparathyroidism. A case of primary hyperparathyroidism is described, in which the level of circulating parathyroid hormone and hypercalcaemia remain entirely unaffected by cimetidine. The drug is implicated in the management of primary hyperparathyroidism unsuitable for surgery, but present evidence, as reviewed, is insufficient to recommend the use of cimetidine in this way.
Introduction
The available precision of serum calcium estimations, and the sensitivity of radioimmune assay techniques, have identified primary hyperparathyroidism as a common disorder. The prevalence of this condition increases with age and the incidence is greater in women. The mechanism of primary hyperparathyroidism is not yet clear, unlike the hallmarks of the disease: hypercalcaemia and increased production of parathyroid hormone (PTH). A series of patients with primary hyperparathyroidism has been reported in which hypersecretion of parathyroid hormone, and to a lesser extent hypercalcaemia, was suppressed by cimetidine in all cases. This present report refers to the view that such suppression may confer no benefit in the hyperparathyroid state, does not always occur and so is unpredictable, and that a place for cimetidine in the diagnosis and management of primary hyperparathyroidism is not proved.
Case report
An 81-year-old white female presented with a cerebrovascular accident. Two 
